Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19

Chun Fan Chen, Chian-Shiu Chien, Yi Ping Yang, Shih Jie Chou, Mong Lien Wang, The Ia Huo, Chih Ching Lin*

*此作品的通信作者

研究成果: Review article同行評審

12 引文 斯高帕斯(Scopus)

摘要

The pandemic infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is widely increasing the patients affiliated with coronavirus disease 2019 (COVID-19) from last December of 2019. It is reported that the entry receptor of SARS-CoV-2 has been confirmed to be angiotensin-converting enzyme 2 (ACE2). Notably, whether the ACE-related inhibitors or drugs modulated ACE2 activity in affecting the viral activity and disease severity of SARS-CoV-2 is still an open question. Dipeptidyl peptidase-4 (DDP-4), a well-known anti-diabetic drug, has been widely used to control the glycemic condition in patients with diabetes. In this article, we are focusing on the impact of ACE inhibitors (ACEI) and DPP4 inhibitors used on SARS-CoV-2 activity and discussions about those drugs that may be related to infectious condition of COVID-19 diseases.

原文English
頁(從 - 到)710-711
頁數2
期刊Journal of the Chinese Medical Association
83
發行號8
DOIs
出版狀態Published - 8月 2020

指紋

深入研究「Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19」主題。共同形成了獨特的指紋。

引用此